Genome Therapeutics Private Limited - Company Profile

It is a pharma private limited company based in Secunderabad, Telangana, India, established in 2011.
2011 Secunderabad, Telangana, India Active
Last Updated:
Access Report
About Genome Therapeutics Private Limited

Genome Therapeutics Private Limited, a active private limited company, was established on 15 July 2011 in Secunderabad, Telangana, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24232TG2011PTC075543. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹1.00 M.

It upholds a compliant status. Its leadership includes Dhavala Madhavi (Managing Director), Ravimohan Dhavala (Whole-Time Director). Past directors included Dhavala Madhavi, Suman Kumar Araveti, Dhavala Venkata Suryanarayana Sarma. It holds ₹6.30 M open charges and no settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at H.No: 1-18-76/1/F2, Vijay Residency, Mes Colony Venkatapuram, Secunderabad, Telangana, 500015.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24232TG2011PTC075543

  • Registration Number

    075543

  • Incorporation Date

    15 July 2011

  • Authorized Capital

    ₹1.00 M

  • Paid-Up Capital

    ₹1.00 M

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 1.00 M
  • Paid Up Capital ₹ 1.00 M
  • Company Age 14 Year, 7 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 6.30 M
  • Revenue Growth **** 0.89%
  • Profit Growth **** -22.84%
  • Ebitda **** -77.45%
  • Net Worth 27.81%
  • Total Assets -1.29%
Company report

Genome Therapeutics Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Genome Therapeutics Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report Banner Element
Who are the key members and board of directors at Genome Therapeutics Private Limited?
Current Directors
Name Designation Appointment Date Status
Dhavala Madhavi Managing Director 15 Jul 2011 Current
Ravimohan Dhavala Whole-Time Director 15 Jul 2011 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 27 Dec 2018 Past
Pramod Abcsdd Director 20 Apr 2013 Past
Pramod Abcsdd Director 16 Aug 2018 Past
Pramod Abcsdd Director 27 Dec 2018 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Genome Therapeutics.

Genome Therapeutics Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 0.89% increase. The company also saw a substantial fall in profitability, with a 22.84% decrease in profit. The company's net worth Soared by an impressive increase of 27.81%.

Genome Therapeutics revenue growth over time
Genome Therapeutics profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 0.89%
*******
*******
*******
*******
Revenue from Operations
*******
 -2.04%
*******
*******
*******
*******
Total Assets
*******
 -1.29%
*******
*******
*******
*******
Profit or Loss
*******
 -22.84%
*******
*******
*******
*******
Net Worth
*******
 27.81%
*******
*******
*******
*******
EBITDA
*******
 -77.45%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Genome Therapeutics?

In 2020, Genome Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹6,300,000.00

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions
  • Others : 0.63 Cr
Latest Charge Details
Date Lender Amount Status
08 Dec 2012 Others ₹6.30 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Genome Therapeutics?

Unlock and access historical data on people associated with Genome Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Genome Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genome Therapeutics's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Genome Therapeutics
Recent Activity within the Organization
  • Annual General Meeting

    Progress on Genome Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.

  • Balance Sheet

    Progress on Genome Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.

  • Charges

    The activity A charge with Others of Rs. 6.30 M registered on 08 Dec 2012 with Charge ID 10446105 was modified on 23 Jun 2016. was completed.

  • Charges

    A charge with Others amounted to Rs. 6.30 M with Charge ID 10446105 was registered on 08 Dec 2012. was recorded as a recent event.

  • Director Appointment

    Dhavala Madhavi was appointed as a Managing Director was appointed as a Managing Director on 15 Jul 2011 & has been associated with this company since 14 years 7 months . was recorded as a recent event.

  • Director Appointment

    Ravimohan Dhavala was appointed as a Whole-time director was appointed as a Whole-time director on 15 Jul 2011 & has been associated with this company since 14 years 7 months . was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Genome Therapeutics Private Limited?

The CIN of Genome Therapeutics Private Limited is U24232TG2011PTC075543.

Where is Genome Therapeutics Private Limited headquartered?

Genome Therapeutics Private Limited is headquartered at H.No: 1-18-76/1/F2, Vijay Residency, Mes Colony Venkatapuram, Secunderabad, Telangana, 500015.

When was Genome Therapeutics Private Limited incorporated?

Genome Therapeutics Private Limited was incorporated on 15 July 2011.

Who are the current directors of Genome Therapeutics Private Limited?

The current directors of Genome Therapeutics Private Limited are

What is the primary industry of Genome Therapeutics Private Limited?

The primary industry of Genome Therapeutics Private Limited is Trade.

Is Genome Therapeutics Private Limited a listed company?

Genome Therapeutics Private Limited is unlisted.

What is the capital structure of Genome Therapeutics Private Limited?

The authorized capital of Genome Therapeutics Private Limited is ₹1.00 M, and the paid-up capital is ₹1.00 M.

What is the compliance status of Genome Therapeutics Private Limited?

The compliance status of Genome Therapeutics Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available